Division

Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibact

The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The Bioinformatics and Computational Biosciences Branch (BCBB) offers a suite of scientific services and resources for the NIAID research community and its collaborators. BCBB provides expertise and computational solutions to researchers at all levels of experience.

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

GUNK center is part of the NIAID Functional Genomics Program. This center was created to investigate the role of previously uncharacterized genes of A. baumannii in its ability to cause human disease. Three projects have been established to:

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.

The Gnotobiotic Animal Facility houses purchased experimental mice in experimental isolators that serve as important resources for researchers studying the microbiome. The mice in this facility are germ-free, i.e., born and raised in absence of live microbes.

NIAID’s microbiome sequencing facility studies the structure and function of the microbiome associated with various hosts and body sites. This facility has one dedicated team and is equipped with an Ilumina MiSeq, which can sequence whole genomes or specific amplicons.

PATRIC, one of the NIAID-funded Bioinformatics Resource Centers, is an information system designed to support the biomedical research community’s work on bacterial infectious diseases via integration of vital pathogen information with rich data and analysis tools.

The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo

Preclinical models support animal models and animal replacement technologies development and refinement as well as testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who aim to integrate experimental biology and computational tools and modeling across temporal and spatial scales towards a better understanding of infectious diseases.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

The Vaccine and Treatment Evaluation Units (VTEUs), supported by the Division of Microbiology and Infectious Diseases (DMID) since the 1960s, comprise a consortium of contracts with academic centers and organizations that provides a ready resource for the conduct of clinical trials to evaluate pr

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).